Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10155987 Methods of predicting resistance to JAK inhibitor therapy

Patent 10155987 was granted and assigned to Dana-Farber Cancer Institute on December, 2018 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

10155987

Date of Patent

December 18, 2018

Patent Application Number

13916169

Date Filed

June 12, 2013

Patent Citations Received

‌

US Patent 11767323 Tricyclic pyridone compounds as JAK2 V617F inhibitors

‌

US Patent 11919908 Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors

‌

US Patent 11780840 Tricyclic urea compounds as JAK2 V617F inhibitors

‌

US Patent 12084430 Tricyclic urea compounds as JAK2 V617F inhibitors

‌

US Patent 11958861 Spirocyclic lactams as JAK2 V617F inhibitors

‌

US Patent 11661422 Tricyclic urea compounds as JAK2 V617F inhibitors

‌

US Patent 11691971 Naphthyridinone compounds as JAK2 V617F inhibitors

‌

US Patent 11753413 Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors

Patent Primary Examiner

‌

Jeanine A. Goldberg

Patent abstract

This present invention provides methods of treating of assessing/monitoring the responsiveness of a cancer cell to JAK inhibitor therapy.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10155987 Methods of predicting resistance to JAK inhibitor therapy

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API